These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 6298424)
61. Relationships between structure and vascular activity in a series of benzylisoquinolines. Chulia S; Ivorra MD; Martinez S; Elorriaga M; Valiente M; Noguera MA; Lugnier C; Advenier C; D'Ocon P Br J Pharmacol; 1997 Oct; 122(3):409-16. PubMed ID: 9351495 [TBL] [Abstract][Full Text] [Related]
62. Effect of inhibitors of cyclic nucleotide phosphodiesterases on electrical and contractile activity of smooth muscle cells. Kovalev IV; Popov AG; Baskakov MB; Minochenko IL; Kilin AA; Borodin YL; Anfinogenova YD; Kapilevich LV; Medvedev MA Bull Exp Biol Med; 2002 Jan; 133(1):38-40. PubMed ID: 12170302 [TBL] [Abstract][Full Text] [Related]
63. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Lugnier C; Schoeffter P; Le Bec A; Strouthou E; Stoclet JC Biochem Pharmacol; 1986 May; 35(10):1743-51. PubMed ID: 2423089 [TBL] [Abstract][Full Text] [Related]
64. Differential effects of various phosphodiesterase inhibitors, pyrimidine and purine compounds, and inorganic phosphates on cyclic CMP, cyclic AMP and cyclic GMP phosphodiesterases. Helfman DM; Kuo JF Biochem Pharmacol; 1982 Jan; 31(1):43-7. PubMed ID: 6277336 [TBL] [Abstract][Full Text] [Related]
66. Actions of papaverine on intestinal smooth muscle and its inhibition of cyclic AMP and cyclic GMP phosphodiesterases. Miyamoto M; Takayanagi I; Ohkubo H; Takagi K Jpn J Pharmacol; 1976 Feb; (1):114-7. PubMed ID: 177797 [No Abstract] [Full Text] [Related]
67. Inhibition of calmodulin-activated cyclic nucleotide phosphodiesterase: multiple binding-sites for tricyclic drugs on calmodulin. Reynolds CH; Claxton PT Biochem Pharmacol; 1982 Feb; 31(3):419-21. PubMed ID: 6280730 [TBL] [Abstract][Full Text] [Related]
68. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors. Rutten K; Prickaerts J; Hendrix M; van der Staay FJ; Sik A; Blokland A Eur J Pharmacol; 2007 Mar; 558(1-3):107-12. PubMed ID: 17207788 [TBL] [Abstract][Full Text] [Related]
69. Effect of carbenoxolone on phosphodiesterase and prostaglandin synthetase activities. Vapaatalo H; Lindén IB; Metsä-Ketelä T; Kangasaho M; Laustiola K Experientia; 1978 Mar; 34(3):384-5. PubMed ID: 204509 [TBL] [Abstract][Full Text] [Related]
70. Cyclic nucleotide phosphodiesterases: critical modulators of endocrine, metabolic, and cardiovascular function and appealing therapeutic targets. Manganiello V Curr Opin Pharmacol; 2011 Dec; 11(6):646-8. PubMed ID: 22079477 [No Abstract] [Full Text] [Related]
71. Cyclic nucleotide phosphodiesterases and human arterial smooth muscle cell proliferation. Rybalkin SD; Bornfeldt KE Thromb Haemost; 1999 Aug; 82(2):424-34. PubMed ID: 10605733 [No Abstract] [Full Text] [Related]
72. HL 725, an extremely potent inhibitor of platelet phosphodiesterase and induced platelet aggregation in vitro. Ruppert D; Weithmann KU Life Sci; 1982 Nov; 31(19):2037-43. PubMed ID: 6294426 [TBL] [Abstract][Full Text] [Related]
73. Differential inhibition of multiple cAMP phosphodiesterase isozymes by isoflavones and tyrphostins. Nichols MR; Morimoto BH Mol Pharmacol; 2000 Apr; 57(4):738-45. PubMed ID: 10727520 [TBL] [Abstract][Full Text] [Related]
74. Characterization of the cyclic nucleotide phosphodiesterase subtypes involved in the regulation of the L-type Ca2+ current in rat ventricular myocytes. Verde I; Vandecasteele G; Lezoualc'h F; Fischmeister R Br J Pharmacol; 1999 May; 127(1):65-74. PubMed ID: 10369457 [TBL] [Abstract][Full Text] [Related]
75. Effect of 3-isobutyl-1-methylxanthine and zaprinast on non-adrenergic non-cholinergic relaxation in the rat gastric fundus. Barbier AJ; Lefebvre RA Eur J Pharmacol; 1992 Jan; 210(3):315-23. PubMed ID: 1377130 [TBL] [Abstract][Full Text] [Related]
76. [Effect of psychotropic preparations on cyclic AMP phosphodiesterase activity in the rat cerebral cortex]. Shchekoldina TG; Vatolkina OE; Libinzon RE Vopr Med Khim; 1978; 24(2):166-9. PubMed ID: 208286 [TBL] [Abstract][Full Text] [Related]
77. PDE inhibitors: a new approach to treat metabolic syndrome? Lugnier C Curr Opin Pharmacol; 2011 Dec; 11(6):698-706. PubMed ID: 22018840 [TBL] [Abstract][Full Text] [Related]
78. Studies on griseolic acid derivatives. III. Synthesis and biological activities of the adducts of griseolic acid and their base exchanged derivatives. Murofushi Y; Kimura M; Kuwano H; Iijima Y; Yamazaki M; Kaneko M Nucleic Acids Symp Ser; 1986; (17):45-8. PubMed ID: 3031627 [TBL] [Abstract][Full Text] [Related]